Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Vildagliptin on Metabolism in Obese T2DM
NCT00380445Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2006
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin with Placebo (2 arms). Primary endpoint: Insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal. Started Jan 2006; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00380445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380445.